High throughput is a key advantage of phage display, but this advantage is squandered in labs not equipped to reformat, express, and purify large numbers of antibodies for characterization. With its High-Throughput Antibody Production Platform, Twist offers a gene-to-protein workflow that eliminates this bottleneck by enabling the production of tens to thousands of diverse antibodies for downstream biophysical and pharmacokinetic screening assays. At the core of this platform is Twist’s silicon-based DNA synthesis process, which can precisely and uniformly write thousands of genes in a single run.
What you will learn from this webinar:
- How Twist bridges the throughput gap between hit identification and characterization in antibody development
- How Twist’s DNA synthesis platform enables high-throughput antibody production
- What antibody formats and specifications are available
- Application case study: How Twist Biopharma team makes best use of the HT IgG Expression service